Not available
Quote | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
Last: | $8.17 |
---|---|
Change Percent: | -1.61% |
Open: | $8.22 |
Close: | $8.17 |
High: | $8.58 |
Low: | $7.81 |
Volume: | 297,127 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
2024-07-23 11:47:46 ET Summary Today, we take a more in-depth look at small-cap biopharma Ocular Therapeutix, Inc. The company is focused on developing therapies for eye conditions using bioresorbable hydrogel-based technology. Ocular's lead clinical candidate, Axpaxli, is und...
2024-07-17 15:35:06 ET Adverum Biotechnologies, Inc. (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 08:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - President & CEO Charles Wykoff - Director of R...
Message Board Posts | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
Subject | By | Source | When |
---|---|---|---|
$ADVM: Watching here at 0.70 now............ readytogooooooo | makinezmoney | investorshub | 01/30/2023 3:01:27 PM |
Adverum lays off 78 employees, bets it all | conix | investorshub | 07/08/2022 2:49:25 PM |
News but PPS not active premarket. | kzivann | investorshub | 01/04/2022 1:26:50 PM |
$ADVM chart on the mend | conix | investorshub | 08/26/2021 12:54:36 PM |
Form 4 - options granted for newly hired | TraderNeoMtl | investorshub | 06/04/2021 1:37:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
Adverum Biotechnologies Inc. Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid contr...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the inte...